nCounter® Vantage 3D™ DNA SNV Assays

Simple, digital detection of single nucleotide variants (SNVs) and small InDels from as little as 5 ng of DNA from FFPE in a single tube. Designed for compatibility with other 3D Biology™ Assays, Vantage 3D DNA SNV Assays deliver reliable SNV detection that may be combined with mRNA, gene fusion, and protein for in-depth characterization of key oncogenesis pathways.

  • Maximum information from only 5 ng of input DNA for SNV and InDel detection
  • Simple protocol, optimized for challenging FFPE samples
  • Validated workflows for cell suspensions, fresh/frozen tissue, and FFPE
  • Concordance with gold standard mutational analysis techniques
  • Sensitivity and Specificity above 95% on solid tumor samples with >5% allele frequency*
  • Customizable and forward-compatible with our growing line of 3D Biology Products
  • Simple, integrated data analysis, eliminating the need for a bioinformatician

*Validated on internal reference materials. Data may vary with the various quality of FFPE samples.

The nCounter® Vantage 3D DNA SNV Assays leverage NanoString’s proven molecular barcode technology. Each SNV panel is designed to detect the mutant allele of interest and a reference allele using a set of probes with novel architecture. The upstream probe (Probe S) has proprietary sequences that become unstable in the presence of a single nucleotide mismatch. The downstream probe (Probe T) is based on existing NanoString probe chemistry. Pools of Probe S and T are combined with an nCounter® molecular barcode SNV TagSet to enable highly specific detection of SNVs in a background of abundant normal tissue alleles.

Integration with the nSolver™ Analysis Software provides a comprehensive detection solution from sample to data. Due to digital barcode chemistry, variants are detected at 1–10% levels.

In the data shown, all assayed variants are detected with >95% confidence (p<0.05 confidence threshold indicated by the dashed pink line).

In collaboration with a team from The University of Texas MD Anderson Cancer Research Center, 5 ng of purified genomic DNA from over 40 different FFPE clinical research samples from a variety of cancer types were assayed with the nCounter® SNV detection chemistry. DNA integrity scores (DIN from TapeStation 2200 analysis) ranged from 2.3 to 6.1 for these samples. Somatic variants that had been previously detected by next-generation sequencing were detected with 98.1% sensitivity, 100.0% specificity, and 99.9% accuracy. Representative results for a selection of these samples are shown in Table 1.

For Research Use Only. Not for use in diagnostic procedures.